Pharmacokinetics of Single-dose Ertugliflozin in Patients With Hepatic Impairment-Reference-Cited by-同舟云学术

Pharmacokinetics of Single-dose Ertugliflozin in Patients With Hepatic Impairment

Published:2018-10 Issue:10 Volume:40 Page:1701-1710
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Sahasrabudhe Vaishali,Terra Steven G.,Hickman Anne,Saur Didier,Raje Sangeeta,Shi Haihong,Matschke Kyle,Zhou Susan,Cutler David L.

Funder

Merck Sharp & Dohme Corp.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference17 articles.

1. International Diabetes Federation. IDF Diabetes Atlas. 7th ed. 2015

2. National diabetes statistics report: estimates of diabetes and its burden in the United States, 2014. Centers for Disease Control and Prevention. Atlanta, GA: US Department of Health and Human Services; 2014.

3. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects;Miao;Drug Metab Dispos,2013

4. Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus;Kalgutkar;Drug Metab Dispos,2011

5. Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study;Aronson;Diabetes Obes Metab,2018

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A potential novel treatment for cirrhosis‐related ascites: Empagliflozin is safe and tolerable in advanced chronic liver disease;British Journal of Clinical Pharmacology;2024-06-16

2. Re‐discover the value of protein binding assessments in hepatic and renal impairment studies and its contributions in drug labels and dose decisions;Clinical and Translational Science;2024-05

3. Pharmacokinetic, toxicological, and clinical considerations for the treatment of type 2 diabetes in patients with liver disease: a comprehensive update;Expert Opinion on Drug Metabolism & Toxicology;2023-08-03

4. Impact of SGLT2 inhibitors on the kidney in people with type 2 diabetes and severely increased albuminuria;Expert Review of Clinical Pharmacology;2022-07-03

5. Population Pharmacokinetic Analyses of Ertugliflozin in Select Ethnic Populations;Clinical Pharmacology in Drug Development;2021-07-02